Armata pharmaceuticals inc
ARMP 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
ARMP 近期報酬表現
-1.19%
Armata pharmaceuticals inc
0.98%
同產業平均
0.02%
S&P500
與 ARMP 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
UPC | Universe pharmaceuticals inc | 1 分 | 5 分 | 2 分 | - | 1 分 | |
URGN | Urogen pharma ltd | 3 分 | 2 分 | 2 分 | 3 分 | 1 分 | |
GLTO | Galecto inc | 2 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
ACHV | Achieve life sciences inc | 3 分 | 5 分 | 1 分 | 1 分 | 1 分 | |
IVA | Inventiva sa | - | 1 分 | 2 分 | - | 1 分 |
- UPC Universe pharmaceuticals inc價值 1 分趨勢 5 分波段 2 分籌碼 -股利 1 分查看更多
ARMP 公司資訊
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.